BC Innovations | Dec 20, 2019
Distillery Therapeutics

An inhibitor of viral latency for imaging, treating EBV-associated cancers

DISEASE CATEGORY: Cancer INDICATION: Nasopharyngeal cancer; lymphoma A peptide-based compound that inhibits EBNA1, which promotes Epstein-Barr virus latency, could be used to image and treat EBV-associated nasopharyngeal cancer and lymphoma. The compound consists of a...
BC Innovations | Mar 13, 2019
Distillery Therapeutics

EBNA1 inhibitors for EBV-dependent cancers

DISEASE CATEGORY: Cancer INDICATION: Nasopharyngeal cancer; lymphoma In vitro , cell culture and mouse studies identified two prodrugs of phenylacetylenyl benzoic acid-based EBNA1 inhibitors that could help treat EBV-dependent lymphoma and nasopharyngeal cancer. Fragment-based screening, chemical...
BioCentury | Jan 13, 2018

JPM jolt

Fifteen biotechs that presented at the 2018 J.P. Morgan Healthcare Conference posted gains of at least 15%, with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) leading the risers after announcing that its board rejected two unsolicited acquisition proposals...
BC Week In Review | Dec 1, 2017
Clinical News

QIMR reports updated Phase I data for MS candidate

Atara Biotherapeutics Inc. (NASDAQ:ATRA) said QIMR Berghofer Medical Research Institute (Brisbane, Australia) reported updated data from a Phase I trial in 10 patients with primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS) showing...
BC Week In Review | Mar 31, 2014
Clinical News

MVA-EBNA/LMP2 vaccine: Phase Ib started

Cancer Research UK said its Drug Development Office ( DDO ) began a U.K. Phase Ib trial to evaluate 3 doses of intradermal MVA-EBNA/LMP2 vaccine every 3 weeks followed by another dose 12 weeks later in 18...
Items per page:
1 - 5 of 5